( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 81 | 先天性副腎皮質酵素欠損症 | 102 |
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 102 / 薬物数 : 72 - (DrugBank : 18) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 71
Showing 1 to 10 of 102 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT06712823 (ClinicalTrials.gov) | February 25, 202520250225 | 27/11/202420241127 | An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894 | An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894 An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy in Participants Treated Wit ... | Congenital Adrenal Hyperplasia;Classic Congenital Adrenal Hyperplasia | Drug: atumelnant (CRN04894) | Crinetics Pharmaceuticals Inc. | NULL | Recruiting | 16 Years | N/A | All | 150 | Phase 2 | United States |
| 2 | NCT05907291 (ClinicalTrials.gov) | July 3, 202320230703 | 8/6/202320230608 | Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adre ... | A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn) A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Ph ... | Congenital Adrenal Hyperplasia;Classic Congenital Adrenal Hyperplasia | Drug: CRN04894 | Crinetics Pharmaceuticals Inc. | NULL | Recruiting | 16 Years | 75 Years | All | 30 | Phase 2 | United States;Argentina;Brazil;Germany;India;Italy;United Kingdom |
| 3 | EUCTR2019-004764-22-LV (EUCTR) | 12/01/202320230112 | 01/09/202220220901 | This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of up to 70 weeks of treatment with tildacerfont in subjects with classic Congenital adrenal hyperplasia (CAH) who have elevated blood hormones at baseline This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that w ... | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia - Efficacy and Safety of Tildacerfont in Adult Subjects with Classic Congenital Adrenal Hyperplasia A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safe ... | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323; ... | Product Name: Tildacerfont Product Code: SPR001 INN or Proposed INN: TILDACERFONT | Spruce Biosciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 72 | Phase 2 | Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Ireland;Korea, Republic of;Poland;Denmark;Italy;Australia;Lithuania;Germany;Estonia Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Irela ... | ||
| 4 | EUCTR2019-004765-40-LV (EUCTR) | 12/01/202320230112 | 01/09/202220220901 | This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce GC use in adult subjects with classic CAH who are on supraphysiologic doses of GC therapy. This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of t ... | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia - Efficacy and Safety of tildacerfont in Reducing Supraphysiologic GC doses in adult subjects with CAH A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 ( ... | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323; ... | Product Name: Tildacerfont Product Code: SPR001 INN or Proposed INN: TILDACERFONT | Spruce Biosciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 2 | Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Ireland;Korea, Republic of;Poland;Denmark;Italy;Australia;Lithuania;Germany;Estonia Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Irela ... | ||
| 5 | NCT03548246 (ClinicalTrials.gov) | January 202320230100 | 24/4/201520150424 | Androgen Reduction in Congenital Adrenal Hyperplasia | A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctiv ... | Congenital Adrenal Hyperplasia | Drug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: Fludrocortisone | University of Texas Southwestern Medical Center | National Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los Angeles;Feinstein Institute for Medical Research National Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los An ... | Withdrawn | 2 Years | 9 Years | All | 0 | Phase 2 | United States |
| 6 | EUCTR2019-004764-22-RO (EUCTR) | 22/12/202220221222 | 10/10/202420241010 | This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of up to 70 weeks of treatment with tildacerfont in subjects with classic Congenital adrenal hyperplasia (CAH) who have elevated blood hormones at baseline This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that w ... | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia - Efficacy and Safety of Tildacerfont in Adult Subjects with Classic Congenital Adrenal Hyperplasia A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safe ... | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323; ... | Product Name: Tildacerfont Product Code: SPR001 INN or Proposed INN: TILDACERFONT | Spruce Biosciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 72 | Phase 2 | Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Netherlands;Sweden;Ireland;Brazil;Korea, Republic of;Denmark;Poland;Italy;Australia;Lithuania;Türkiye;Germany;Estonia Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Netherlands;Sweden;Ireland;Braz ... | ||
| 7 | EUCTR2019-004765-40-RO (EUCTR) | 22/12/202220221222 | 10/10/202420241010 | This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce GC use in adult subjects with classic CAH who are on supraphysiologic doses of GC therapy. This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of t ... | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia - Efficacy and Safety of tildacerfont in Reducing Supraphysiologic GC doses in adult subjects with CAH A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 ( ... | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323; ... | Product Name: Tildacerfont Product Code: SPR001 INN or Proposed INN: TILDACERFONT | Spruce Biosciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 2 | Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Netherlands;Sweden;Ireland;Brazil;Korea, Republic of;Denmark;Poland;Italy;Australia;Lithuania;Türkiye;Germany;Estonia Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Netherlands;Sweden;Ireland;Braz ... | ||
| 8 | NCT05669950 (ClinicalTrials.gov) | December 19, 202220221219 | 20/12/202220221220 | Study of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia | A Multi-site, Open-label, Sequential-group, Multiple-ascending-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Patients With Congenital Adrenal Hyperplasia A Multi-site, Open-label, Sequential-group, Multiple-ascending-dose Study to Investigate the Safety, ... | Congenital Adrenal Hyperplasia | Drug: Lu AG13909 | H. Lundbeck A/S | NULL | Recruiting | 18 Years | 55 Years | All | 12 | Phase 1 | Sweden;United Kingdom |
| 9 | EUCTR2019-004764-22-LT (EUCTR) | 22/11/202220221122 | 28/06/202220220628 | This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of up to 70 weeks of treatment with tildacerfont in subjects with classic Congenital adrenal hyperplasia (CAH) who have elevated blood hormones at baseline This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that w ... | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia - Efficacy and Safety of Tildacerfont in Adult Subjects with Classic Congenital Adrenal Hyperplasia A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safe ... | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323; ... | Product Name: Tildacerfont Product Code: SPR001 INN or Proposed INN: TILDACERFONT | Spruce Biosciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 72 | Phase 2 | Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Poland;Denmark;Italy;Lithuania;Australia;Germany;Estonia Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Polan ... | ||
| 10 | EUCTR2019-004765-40-LT (EUCTR) | 22/11/202220221122 | 29/06/202220220629 | This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce GC use in adult subjects with classic CAH who are on supraphysiologic doses of GC therapy. This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of t ... | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia - Efficacy and Safety of tildacerfont in Reducing Supraphysiologic GC doses in adult subjects with CAH A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 ( ... | Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Classic Congenital Adrenal Hyperplasia MedDRA version: 20.0;Level: LLT;Classification code 10010323; ... | Product Name: Tildacerfont Product Code: SPR001 INN or Proposed INN: TILDACERFONT | Spruce Biosciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 2 | Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Poland;Denmark;Italy;Lithuania;Australia;Germany;Estonia Romania;United States;United Kingdom;Switzerland;Spain;Canada;Latvia;Sweden;Netherlands;Turkey;Polan ... |